+1803294983432
customer.service@microbix.com
External Quality Controls
SARS Complete Panel
Respiratory Viral Panel
DxTM Viral Transport Medium
Custom Vial Filling Solutions
Proudly Supporting Over 100+ Customers with Leading Diagnostic Solutions
“Microbix approached us before the pandemic started, and the relationship developed so easily and quickly that we formalized our collaboration in 2020. Along with their excellent technical capabilities, they have successfully developed relationships with many diagnostics manufacturers around the world. We are pleased that our FLOQSwabs® are their exclusive choice for their growing line of swab formatted QAPs™”
Gaetano Natale, Chief Commercial Officer.
The Microbix Difference
Our Quality Commitment
By choosing Microbix Biosystems Inc., you are aligning with a partner certified to the latest ISO standards and dedicated to delivering products that truly set the benchmark for quality in the industry.
Decades of Expertise
With over three decades of experience in the global diagnostics industry, Microbix has established a reputation as a leading infectious disease diagnostic manufacturer.
Widespread Customer Acceptance
Microbix’s products have consistently earned widespread recognition and trust from customers due to their superior reliability.
Download Our Full Product Catalogue
News & Insights from Our Diagnostics Experts
-
Microbix Updates Investor Presentation on its Website
Microbix announces the commercial usage of its first recombinant antigen product, the nucleocapsid protein of the SARS-CoV-2 virus (COVID-19), in its quality assessment products (“QAPs™”) and its availability at commercial scale for test manufacturers.
-
Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen
Microbix announces the commercial usage of its first recombinant antigen product, the nucleocapsid protein of the SARS-CoV-2 virus (COVID-19), in its quality assessment products (“QAPs™”) and its availability at commercial scale for test manufacturers.
-
Microbix Reports Results for Q4 and Fiscal 2025
Full-Year Revenues of $18.6 million and Net Loss of $2.2 million MISSISSAUGA, CANADA, December 18, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“2025” and “Q4”) with revenues for those periods reflecting…
Speak to a Microbix Products Customer Service Representative
Let our knowledgeable experts help you secure your Microbix infectious disease diagnostics products supply today.
